Literature DB >> 24284333

Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.

Cecilia Arana Yi1, Ghayathri Jeyakumar1, Pedro Medina2, Jorge Cortes1, Sherry Pierce1, Carlos Bueso-Ramos3, Hagop Kantarjian1, Srdan Verstovsek4.   

Abstract

Primary myelofibrosis (PMF) is myeloproliferative neoplasm whose diagnosis is based on a combination of clinical and pathology criteria. We evaluated 560 consecutive patients who were diagnosed with PMF upon a referral to our center and evaluated the frequency of and reasons for diagnostic discordance. Discordance in the diagnosis was found in 70 (12.5%) patients. Discordant cases had a significantly lower grade of bone marrow fibrosis (grade 0-1), more likely to be JAK2V617F-mutation negative, and have no peripheral blood blasts, possibly explaining the difficulty in making a proper diagnosis and underscoring the need for a complete evaluation at a tertiary center.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diagnostic discrepancy; JAKV617F mutation; Primary myelofibrosis

Mesh:

Substances:

Year:  2013        PMID: 24284333      PMCID: PMC4406374          DOI: 10.1016/j.leukres.2013.11.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  15 in total

Review 1.  Pathogenesis of myelofibrosis with myeloid metaplasia.

Authors:  Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2005-11-20       Impact factor: 44.544

2.  Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Leonhard Müllauer; Veronika Buxhofer-Ausch; Bettina Gisslinger; Heinz Gisslinger
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

3.  Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.

Authors:  Kiran Naqvi; Elias Jabbour; Carlos Bueso-Ramos; Sherry Pierce; Gautam Borthakur; Zeev Estrov; Farhad Ravandi; Stefan Faderl; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

Review 4.  Myelofibrosis with myeloid metaplasia.

Authors:  A Tefferi
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

5.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Authors:  Naseema Gangat; Domenica Caramazza; Rakhee Vaidya; Geeta George; Kebede Begna; Susan Schwager; Daniel Van Dyke; Curtis Hanson; Wenting Wu; Animesh Pardanani; Francisco Cervantes; Francesco Passamonti; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

6.  Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.

Authors:  Ayalew Tefferi; Rakhee Vaidya; Domenica Caramazza; Christy Finke; Terra Lasho; Animesh Pardanani
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

7.  European consensus on grading bone marrow fibrosis and assessment of cellularity.

Authors:  Jürgen Thiele; Hans Michael Kvasnicka; Fabio Facchetti; Vito Franco; Jon van der Walt; Attilio Orazi
Journal:  Haematologica       Date:  2005-08       Impact factor: 9.941

Review 8.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

9.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

Review 10.  Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.

Authors:  Ayalew Tefferi
Journal:  Am J Hematol       Date:  2013-02       Impact factor: 10.047

View more
  2 in total

1.  The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading.

Authors:  O Pozdnyakova; S Rodig; S Bhandarkar; K Wu; J Thiele; R Hasserjian
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

2.  Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.

Authors:  Serena Rupoli; Gaia Goteri; Paola Picardi; Giorgia Micucci; Lucia Canafoglia; Anna Rita Scortechini; Irene Federici; Federica Giantomassi; Lidia Da Lio; Antonio Zizzi; Elisa Honorati; Pietro Leoni
Journal:  Diagn Pathol       Date:  2015-04-16       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.